COVID vaccine manufacturers to make billions from selling third dose

Pfizer may receive $26 billion from the sales of the third dose of its coronavirus vaccine in 2022, Report informs with reference to the Morningstar financial company.

The company’s sales forecast for this year is $4 billion.

Another vaccine maker, Moderna, might earn $2 billion this year and $14 billion next year.

At the same time, Morningstar analysts believe that sales might increase significantly next year as countries approve the third dose.